Law firms investigate Humacyte for securities fraud, alleging false statements delayed FDA approval.

Rosen Law Firm and Faruqi & Faruqi are investigating Humacyte, Inc. for securities fraud, alleging the company made false statements about its Durham facility, leading to delayed FDA approval of its vascular product. Investors who bought securities between May 10 and October 17, 2024, are encouraged to join the lawsuit or discuss potential claims. The deadline to join the class action is January 17, 2025.